Skip to search formSkip to main contentSkip to account menu
INTRODUCTION
TLDR
A symposium of nationally recognized experts was convened to address the issue of informed consent in research involving people with Alzheimer disease (AD) on November 1, 2001, in Lubbock, Texas, and general agreement that the present informed consent rules, statutes, and beliefs are an impediment to the conduct of research carrying moderate to high risk in people with AD.
View on Wolters Kluwer
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple…
TLDR
Copolymer 1 (Copaxone) was studied in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis and significantly more patients receiving copolym 1 were found to have improved and more receiving placebo worsened.
View on PubMed
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
TLDR
It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.
View on Publisher
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
TLDR
The clinical benefit of glatiramer acetate for both the relapse rate and for neurologic disability was sustained at the end of the extension trial.
View on Wolters Kluwer
Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments
TLDR
Dextromethorphan/quinidine, the first FDA-approved PBA medication, is a novel therapy with antiglutamatergic actions, and as life expectancy lengthens and neurologic settings of PBA become more common, the need for treatment can be expected to increase.
View on Taylor & Francis
Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: sensitivity, specificity, and positive and negative predictive powers.
View on PubMed
What Makes a Good Clinical Teacher in Medicine? A Review of the Literature
TLDR
Excellent clinical teaching, although multifactorial, transcends ordinary teaching and is characterized by inspiring, supporting, actively involving, and communicating with students.
View on Wolters Kluwer
Affective disorders in multiple sclerosis. Review and recommendations for clinical research.
TLDR
English-language studies of euphoria, pathological laughing and weeping, depression, and bipolar disorder are presented, methodological limitations are described, and areas for future clinical research are suggested.
View on PubMed
Anxiety and Parkinson's disease.
TLDR
The optimal pharmacologic treatment for anxiety in patients with PD has not been established, but available information about the use of anxiolytics in PD is reviewed.
View on PubMed
Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect
To evaluate dextromethorphan combined with ultra low‐dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
View on Wiley
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License